 TORRANCE, Calif., Oct. 12, 2021 PRNewswire -- Emmaus Life Sciences, Inc. OTCQX: EMMA, a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the signing of an agreement with Kainos Medicine, Inc. Kainos, granting Emmaus an exclusive license to patent rights, know-how and other intellectual property relating to Kainos novel IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers including leukemia, lymphoma and solid tumors. 